Received FDA Accelerated Approval For VOYXACT (Sibeprenlimab-Szsi) For The Reduction Of Proteinuria In Adults With Primary Immunoglobulin A Nephropathy (IgAN) At Risk For Disease Progression
US FDA approves Otsuka's kidney disease drug (updated)
Brief: FDA Approves Use Of Voyxact To Reduce Proteinuria In Primary Immunoglobulin
Brief: EMA's CHMP Announces Positive Recommendation On Extension Of Therapeutic Indications For Koselugo
Table: Otsuka Holdings -9-MTH group results (IFRS)
Shares of Asian drugmakers drop after Trump threatens tariffs (updated)
Brief: Otsuka And Lundbeck Receive Complete Response Letter From U.S. FDA For SNDA Of Rexulti® (Brexpiprazole) In Combination With Sertraline For The Treatment Of Adults With PTSD
Table: Otsuka Holdings 6-MTH group results (IFRS)
2025 6-month group forecast(IFRS)
Unit Otsuka Medical Devices Co To Sell Part Of Its Shares In MicroPort Scientific Corp
Nikkei falls as traders lock in gains after US trade deal rally (updated)
Nikkei falls as traders lock in gains after US trade deal rally
Otsuka And Lundbeck Issue Statement On U.S. FDA Advisory Committee Meeting On REXULTI For The Treatment Of Adults With PTSD
US FDA advisers vote against Otsuka's PTSD combination treatment (updated)
US FDA advisers vote against Otsuka's PTSD combination treatment
FDA staff raises efficacy concerns for Otsuka's PTSD combination drug (updated)
FDA staff raises efficacy concerns for Otsuka's PTSD combination drug
Vera Therapeutics falls after kidney drug data from rival Otsuka
Otsuka's kidney disease drug shows over 50% reduction in protein in urine (updated)